The stock of NxStage Medical, Inc. (NASDAQ:NXTM) hit a new 52-week high and has $35.76 target or 35.00% above today’s $26.49 share price. The 6 months bullish chart indicates low risk for the $1.78 billion company. The 1-year high was reported on Nov, 11 by Barchart.com. If the $35.76 price target is reached, the company will be worth $623.00M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 3.52% or $0.9 during the last trading session, hitting $26.49. About 605,230 shares traded hands or 43.90% up from the average. NxStage Medical, Inc. (NASDAQ:NXTM) has risen 77.96% since April 11, 2016 and is uptrending. It has outperformed by 71.81% the S&P500.
NxStage Medical, Inc. (NASDAQ:NXTM) Ratings Coverage
Out of 6 analysts covering NxStage Medical (NASDAQ:NXTM), 5 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 83% are positive. NxStage Medical has been the topic of 7 analyst reports since November 4, 2015 according to StockzIntelligence Inc. The stock of NxStage Medical, Inc. (NASDAQ:NXTM) earned “Buy” rating by Canaccord Genuity on Tuesday, August 2. The firm has “Outperform” rating by Northland Capital given on Tuesday, June 28. Piper Jaffray reinitiated NxStage Medical, Inc. (NASDAQ:NXTM) rating on Thursday, March 31. Piper Jaffray has “Overweight” rating and $18.50 price target. The firm has “Buy” rating given on Friday, December 18 by BTIG Research. On Friday, December 11 the stock rating was initiated by Sterne Agee CRT with “Buy”.
According to Zacks Investment Research, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.”
Insitutional Activity: The institutional sentiment decreased to 0.97 in 2016 Q2. Its down 0.37, from 1.34 in 2016Q1. The ratio dropped, as 22 funds sold all NxStage Medical, Inc. shares owned while 45 reduced positions. 26 funds bought stakes while 39 increased positions. They now own 61.50 million shares or 4.11% more from 59.07 million shares in 2016Q1.
Qs Invsts Lc accumulated 137,622 shares or 0.03% of the stock. Hbk Invs Limited Partnership reported 54,300 shares or 0.01% of all its holdings. Bank Of Montreal Can has 0.02% invested in the company for 687,791 shares. Gp One Trading Ltd Partnership last reported 0% of its portfolio in the stock. Grandeur Peak Global Advsrs Llc reported 73,600 shares or 0.22% of all its holdings. Portolan Cap Mgmt Limited Liability Corporation last reported 215,810 shares in the company. Teachers Advsrs, a New York-based fund reported 112,655 shares. Legal & General Gru Pcl last reported 0% of its portfolio in the stock. Great West Life Assurance Can reported 8,228 shares or 0% of all its holdings. Blackrock Fund Advisors reported 1.82M shares or 0.01% of all its holdings. Tiaa Cref Investment Management Limited Liability last reported 0% of its portfolio in the stock. Sectoral Asset Mgmt Inc accumulated 1.83 million shares or 4.09% of the stock. Jennison Limited Liability holds 0.04% or 1.52M shares in its portfolio. Citigroup accumulated 0% or 5,572 shares. American Intl Inc has 0% invested in the company for 36,655 shares.
Insider Transactions: Since May 12, 2016, the stock had 0 insider purchases, and 1 insider sale for $69,930 net activity. MOORE CRAIG W sold 3,000 shares worth $69,930. The insider Turk Joseph E Jr sold $26,835.
More recent NxStage Medical, Inc. (NASDAQ:NXTM) news were published by: Fool.com which released: “Here’s Why NxStage Medical, Inc.’s Stock Is Popping Today” on November 03, 2016. Also Fool.com published the news titled: “Home and Critical Care Drive NxStage Medical, Inc. Q2 Improvement” on August 04, 2016. Fool.com‘s news article titled: “Why NxStage Medical, Inc. Guided Lower Today” with publication date: February 10, 2016 was also an interesting one.
NXTM Company Profile
NxStage Medical, Inc., incorporated on October 20, 1998, is a medical technology company. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. The Firm operates through three divisions: System One, In-Center and Services. The Firm offers its services and products to various markets, such as home, critical care and in-center. The Company’s primary product, the System One, delivers the therapeutic flexibility and clinical benefits associated with dialysis machines that can be used by healthcare professionals and trained lay users alike in various settings, including patient homes, as well as traditional care settings, such as hospitals and dialysis centers. The Firm operates NxStage Kidney Care dialysis centers that treat end-stage renal disease patients directly.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.